Current Neuro-Oncology

Volume 28 Number 2
20 January 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 2, 20 January

Zeng W, Wang P, Fang S, Ge S, Jia W, Peng S, Wang M, Qin X, Zhang W, Gao J, Su X, Yuan G, Wu J, Liu Y, Wang Y, Lu H, Mu R, Wu F, Chang Q, Jin G, Meng F, Zhang J, Liu F.
ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: a single-arm, phase 1/2 study.
Neuro Oncol. 2026 Jan 12:noag005. doi: 10.1093/neuonc/noag005. PMID: 41527280. Interventional study. ˍ

El Ghalbouni A, Snijders TJ, Tolboom N, Braat AJAT.
Near complete response recurrent glioblastoma after treatment with [¹³¹I]-Iodofalan.
Eur J Nucl Med Mol Imaging. 2026 Jan 14. doi: 10.1007/s00259-025-07742-w. PMID: 41533060. Case report. ˍ

Salama AKS, Wang V, Macrae ER, Park JI, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF^V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
JCO Precis Oncol. 2026 Jan 14;10:e2500338. doi: 10.1200/PO-25-00338. PMID: 41533998. Interventional study. ˍ

Singh DJ, Prabhakar H, Kapoor I, Pandia MP, Pandey S.
Opioid-free Anesthesia for Craniotomy in Supratentorial Tumors: An Open-labeled Single-blinded Randomized Controlled Study.
J Neurosurg Anesthesiol. 2026 Jan 15. doi: 10.1097/ANA.0000000000001089. PMID: 41537278. Interventional study˰ ˍ

Zhang J, Wang D, Liu G, Bu C, Lv G, Li M, Wei S, Zhang Z, Gao Y, Yan Z, Ma C, Zhao R, Wang M, Shi Y, Bu X.
Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial.
Cancer. 2026 Jan 15;132(2):e70253. doi: 10.1002/cncr.70253. PMID: 41533333. Interventional study˰ ˍ

Lind LM, Fischl A, Goettl E, Herr W, Kaiser U, Koelbl O, Linker R, Maurer J, Riemenschneider MJ, Schmidt NO, Proescholdt M, Pukrop T, Hau P, Rechenmacher M, Bumes E.
Palliative care interventions and outcome in patients with glioblastoma - a retrospective, single-center study.
BMC Palliat Care. 2026 Jan 16;25(1):29. doi: 10.1186/s12904-026-01987-4. PMID: 41546074. Observational study. ˍ

Moraes FY, Isen J, Perry J, Laperriere N, Brandes A, Menten J, Phillips C, Fay M, Nishikawa R, Mason WP, Cairncross JG, Roa W, Ding K, O'Callaghan C.
Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial.
J Neurooncol. 2026 Jan 19;176(3):171. doi: 10.1007/s11060-025-05399-x. PMID: 41553596. Observational study˰ ˍ

Nobre L, Ramaswamy V, Coleman C, Dhall G, Senapati A, Toledano H, Jabado N, Bouffet E, Lafay-Cousin L.
High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood.
J Neurooncol. 2026 Jan 19;176(3):172. doi: 10.1007/s11060-026-05425-6. PMID: 41553441. Observational study˰ ˍ

Diao Y, Liang H, Wang Y, Hang L, Fang L, Qu H, Sun H, Li W, Jiang G.
Exploring the diagnostic value of dynamic contrast-enhanced and diffusion tensor imaging of intratumoural and peritumoural high-grade gliomas for distinguishing treatment response from tumour progression.
Clin Radiol. 2025 Oct 7;93:107114. doi: 10.1016/j.crad.2025.107114. PMID: 41529314. Observational study. ˍ

Kameda-Smith MM, Lannon M, Almojuela A, MacLean MA, Persad A, Sader N, Kulamurugan A, Manoranjan B, Erker C, Aminnejad M, Cooks B, Vitali AM, Hader W, Walling S, Daniel McNeely P, Yarascavitch B, Ajani O, Farrokhyar F, Fleming A, Singh SK; Canadian Neurosurgery Research Collaborative (CNRC) in conjunction with the McMaster Pediatric Brain Tumour Study Group (PBTSG).
National multicentered retrospective review of salvage therapy for pediatric medulloblastoma: a Canadian experience.
Childs Nerv Syst. 2025 Dec 1;41(1):391. doi: 10.1007/s00381-025-07026-6. PMID: 41324672. Observational study˰ ˍ

Rocha Grade D, Soares T, João DA, Lima T, Marques Baptista A.
Extremely Long-Term Glioblastoma Survival (Ten Years): A Possible Role of Immune Modulation From Pre-existing Diseases.
Cureus. 2025 Dec 11;17(12):e98984. doi: 10.7759/cureus.98984. PMID: 41523441. Case report. ˍ

Tong Y, Rao H, Li Y, Chang C, Yang Y.
Efficacy and survival outcomes of bevacizumab plus minocycline for glioblastoma.
Am J Transl Res. 2025 Dec 15;17(12):9846-9858. doi: 10.62347/LDSW5672. PMID: 41552322. Observational study. ˍ

Pinson H, De Rudder C, De Backer L, Van Sinay A, Boterberg T, Hallaert G.
Temporal muscle measurements as predictor for outcome in a cohort of IDH-wildtype glioblastoma patients.
Brain Spine. 2025 Dec 23;6:105914. doi: 10.1016/j.bas.2025.105914. PMID: 41551865. Observational study. ˍ

Kesumayadi I, Kambe A, Kanda H, Hosoya T, Sakamoto M, Kurosaki M.
Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression.
Sci Rep. 2026 Jan 10. doi: 10.1038/s41598-026-35550-1. PMID: 41520070. Observational study. ˍ